

Cite this: *Analyst*, 2015, **140**, 3910

Chemical analysis of multicellular tumour spheroids

L. E. Jamieson,^a D. J. Harrison^b and C. J. Campbell^{*a}

Conventional two dimensional (2D) monolayer cell culture has been considered the 'gold standard' technique for *in vitro* cellular experiments. However, the need for a model that better mimics the three dimensional (3D) architecture of tissue *in vivo* has led to the development of Multicellular Tumour Spheroids (MTS) as a 3D tissue culture model. To some extent MTS mimic the environment of *in vivo* tumours where, for example, oxygen and nutrient gradients develop, protein expression changes and cells form a spherical structure with regions of proliferation, senescence and necrosis. This review focuses on the development of techniques for chemical analysis of MTS as a tool for understanding *in vivo* tumours and a platform for more effective drug and therapy discovery. While traditional monolayer techniques can be translated to 3D models, these often fail to provide the desired spatial resolution and z-penetration for live cell imaging. More recently developed techniques for overcoming these problems will be discussed with particular reference to advances in instrument technology for achieving the increased spatial resolution and imaging depth required.

Received 16th March 2015,
Accepted 23rd April 2015

DOI: 10.1039/c5an00524h

www.rsc.org/analyst

Introduction

Cell culture is used to study all aspects of cellular characteristics and function and for *in vitro* testing of drug candidates and therapies. Conventionally cells are cultured on a flat surface in a petri dish or flask where their primary physical contacts are with the substrate on which they are growing and

the culture medium surrounding them, with very little cell–cell interaction.¹ This suffers from the major drawback that the cells are not in a realistic physiological environment. *In vivo*, cells are in a 3D environment with the major physical contact being cell–cell interactions with surrounding cells, and cell–matrix interactions with the extracellular matrix (ECM). This 3D environment introduces complexity that is not observed in traditional monolayer cell culture. As a result, drugs and disease therapies that prove effective in the monolayer cell culture models often fail to carry this efficacy forward into *in vivo* trials.² While tissue explants grown in culture provide a step between monolayer cell culture and the *in vivo* environ-

^aEaStCHEM, School of Chemistry, University of Edinburgh, Edinburgh, EH9 3JJ, UK.
E-mail: colin.campbell@ed.ac.uk

^bMedical and Biological Sciences Building, University of St Andrews, North Haugh,
St Andrews, Fife KY16 9TF, UK



L. E. Jamieson

Lauren Jamieson graduated with a BSc (Hons) in Chemistry with Medicinal Chemistry in 2012 from the University of St Andrews. She subsequently started her PhD at the University of Edinburgh under the supervision of Dr Colin Campbell and Prof. David Harrison. Her research focuses on using SERS nanosensors to measure redox potential and pH in multicellular tumour spheroids (MTS).



D. J. Harrison

David Harrison is a clinician with an interest in cellular determinants of response to injury and quantitative systems biology application in pathology. He is Professor of Pathology in University of St Andrews, with an honorary professorship in University of Edinburgh, and he is Director of Laboratory Medicine in Edinburgh overseeing clinical provision in four hospitals. He chairs the steering group of the Framework 7 concerted action

CASyM, drawing up the roadmap for implementation of systems medicine in Europe.

ment, access to such samples is limited. There is therefore a need for an *in vitro* model of tumour biology that mimics better the 3D environment that exists *in vivo* without the added ethics, health, safety, cost and availability limitations encountered when using animal models or explanted tissue.

Multicellular tumour spheroids (MTS) have become increasingly used for the study of cell function and testing of drugs as they satisfy the requirement for a more complex and physiologically relevant cell culture model. Attempts have been made to incorporate cells of different types, for example by mixing cancer cell lines with non-malignant fibroblast or other stromal cells.^{2,3} In particular MTS are used as an *ex vivo* model of cancer. Importantly, the blood supply to many cancers *in vivo* is poor due to rapidly proliferating cells producing cellular masses where the centre regions may be far from the well organised vasculature of the body. Cancer cells are capable of signalling for the formation of new blood vessels *via* proteins such as vascular endothelial growth factor (VEGF),⁴ however the resulting vasculature is disorganised and leaky so does not effectively deliver oxygen and nutrients to the tumour. As a result, concentration gradients develop in factors including oxygen, nutrients and pH (Fig. 1).⁵ The concentration gradients developed *in vivo* are mimicked by MTS where a radial structure develops with a core that is frequently necrotic, surrounding quiescent cells and an outer proliferating layer (Fig. 1).⁶

The microenvironments⁴ that develop in cancer give rise to local heterogeneity in aspects including gene expression and regulation; cell differentiation, proliferation, viability and death; drug metabolism; and response to stimuli (Fig. 1).⁸ This combination of factors leads to increased complexity when considering drug and therapy treatments *in vivo* compared to simple monolayer cell culture assays. For example, increased resistance to cytotoxic drugs and ionising radiation *in vivo* may be a direct consequence of the microenvironment that develops.^{5,9} This makes the use of MTS in drug and




Fig. 1 MTS organisation and radial changes that are established or predicted (adapted from Lin R. *et al.*⁷).

therapy development increasingly important as they mimic better the *in vivo* environment in comparison to traditional monolayer culture models. This review brings together the current techniques and enabling technologies for chemical analysis of various characteristics of MTS. It summarises the latest technologies being used to improve analysis of MTS as an important model of tumour biology highlighting where there is room for improvement in chemical, spatial and temporal resolution.

Methods for growing MTS

A variety of techniques have been developed for the formation of MTS. The basic requirement for MTS formation is that adhesions between cells is stronger than that between cells and the substrate they are grown on.⁷ The first examples of multicellular spheroid growth were performed by Holtfreter¹⁰ who was studying gastrulation, and Moscona and Moscona¹¹ who demonstrated the aggregation of isolated chick chondrogenic and myogenic cells.⁵ These initial studies formed non-tumour multicellular spheroids with the advantage that they better mimic the *in vivo* 3D environment. While this review focuses on MTS as an *in vitro* cancer tumour model, techniques discussed are equally applicable to non-tumour spheroids and organoids.

Depending on the culture technique and cell type employed, spheroids are formed in varying quantities, over various time periods and with varying degrees of homogeneity and the particular technique used is likely to be guided by the particular application being employed. For example, using spinner flasks allows large quantities of MTS to be formed but these often lack homogeneity while using the hanging drop technique allows much more homogenous and uniform MTS formation but is difficult to perform on a large scale.^{1,7}

Fig. 2 illustrates some of the techniques employed for MTS formation.



C. J. Campbell

Colin Campbell is Director of the EPSRC and MRC CDT in Optical Medical Imaging and a Senior Lecturer in the School of Chemistry at the University of Edinburgh. He works exclusively at the interface with biology and medicine. His interest is primarily in understanding the role of redox processes in determining phenotype and his research primarily focuses on developing new biophysical techniques to measure cellular redox states

and developing new approaches to analyse, visualize and interpret redox biology in cells and tissues.






Fig. 2 Examples of methods of MTS formation: (a) MTS being grown using the basic hanging drop technique, (b) MTS growing in spinner flasks, (c) MTS being grown on microcarrier beads and (d) cells (red) growing in a scaffold of alginate gel (green), an example of the start of MTS growth in a scaffold of NovaMatrix-3D™.

Spontaneous aggregation

The simplest method for the formation of MTS is spontaneous aggregation, where the cells spontaneously cluster to form cell aggregates that grow in 3D. Technically these are cell aggregates rather than MTS and only a few cell lines grow in this way – MDA-MB-435 human breast cancer cells being one example.¹ Due to these limitations, a variety of other more complex methods have been developed.

Hanging drop

In its simplest form, the hanging drop methods involves growing MTS from drops of cell suspension in culture media suspended from the lid of a petri dish (Fig. 2a). Cells aggregate in the drops which remain in place by surface tension and then grow into MTS.⁷ More recent technologies have developed multiwell plates for the growth of MTS using the hanging drop method including the Perfecta3D™ Hanging Drop Plates¹² where the new design allows for easier treatment, media exchange and handling of the MTS. Growing MTS using this method allows for the formation of MTS of uniform size although it is difficult to culture large numbers of MTS in this way.¹³

Gyratory methods and spinner flasks

A popular method for formation of large numbers of MTS is the spinner flask method (Fig. 2b). This involves putting a suspension of cells in media into a flask which is constantly kept stirring. Due to the constant motion, cells are not given the chance to adhere to surfaces in the flask and therefore aggregate together and grow to form MTS. Similarly gyratory methods involve placing the cell suspension in flasks that are

put into incubators where they are rotated by gyratory motions. Both of these techniques allow for larger quantities of MTS to be formed however the drawback is that the MTS formed are heterogeneous in size and shape and the constant rotary motion could mechanically alter the MTS.^{1,7}

Non adhesive plates/liquid overlay

Another popular method for MTS formation involves growing cells in plates with substrates that limit cell adhesion. This relies on the cell–cell adhesion being stronger than the cell–substrate adhesion, encouraging cells to aggregate and form MTS rather than adhere to the substrate in the plate. Using substrates such as agarose,¹⁴ polyethylene glycol (PEG) and polydimethylsiloxane (PDMS) to coat the bottom of plates allows for this type of MTS formation.¹⁵

Microcarrier beads

Microcarrier beads are small 100–400 μm diameter¹ solid beads on which cells are grown in 3D (Fig. 2c). They can be produced from various materials including dextran and cellulose. Microcarrier beads are available at a low cost commercially and tend to allow spheroid formation from primary cells and transformed cell lines as well as cell types which are normally difficult to grow such as endothelial cells. As the beads form the central regions of these cultures there is less likelihood that a necrotic core will develop and therefore these models are more representative of healthy cells growing *in vivo* as opposed to cancer tumour cell lines.¹⁶

Scaffolds

Scaffolds are extracellular matrix (ECM) mimics that can either be synthetic *e.g.* polyglycolic acid or naturally derived *e.g.* type I collagen and Matrigel® (Fig. 2d). They are highly porous 3D matrices which allow cells to attach, proliferate and differentiate and guide cells to produce 3D MTS structures.² 3D Biotek have developed culture kits based on the biodegradable scaffold poly(γ -caprolactone) (PCL).¹⁷

Microwells and microfluidics

A relatively recent advancement in the growth of uniform MTS on a large scale is the use of microwells and microfluidics, enabled by the development of microprinting techniques including photolithography and soft lithography.⁷ Arrays of wells are printed into materials such as polyethylene glycol (PEG), polydimethylsiloxane (PDMS) and agarose which are nonadherent to cells.¹⁸ Thousands of wells can be printed in a single substrate with a defined diameter. When a cell suspension is added to such a printed substrate in a plate, cells settle into the wells such that each well contains an equal number of cells that then form MTS homogenous in size and shape. Size and geometry of MTS formed can be controlled by well shape and size. Recently many systems have been developed on microfluidic chips patterned with microwells and microchannels such that MTS can be formed in arrays and, for example, drugs can be delivered to these systems.^{2,15}



Chemical analysis of MTS – understanding tumour physiology

A variety of techniques have been developed to investigate the physiology of MTS and their changes in response to drugs and therapy. These techniques include advances in instrument technology to allow imaging in real time, in 3D; a variety of techniques to allow observation of variation in oxygen, hypoxia, pH and nutrients; and methods to measure protein expression as well as general growth characteristics and morphology.

Advances in instrument technology to analyse MTS

In the simplest form standard histological methods are used to visualise MTS but this involves fixing and sectioning the samples, which introduces artefacts and does not allow the observation of dynamic processes. Conventional histological dyes also have low spatial resolution.⁸ New instrumentation has allowed MTS to be analysed *in situ*.

Confocal microscopy can be used to view MTS with *z* resolution but penetration depths are limited and may not allow full *z* penetration through MTS. Efforts have been made to improve resolution and penetration depth of confocal microscopy to achieve the best images including the use of borosilicate glass bottoms on dishes as opposed to polystyrene, a water immersion microscope objective instead of a dry objective and increased laser power/light output at deeper image depths.¹⁹ While better resolution and increased *z* penetration was observed, the *z* penetration was still limited to 350 μm with this technique meaning it was unable to visualise the entire depth of a MTS.

Two and multi photon microscopy have been used for imaging 3D samples as they can give a two to three fold increase in penetration depth in comparison to one photon confocal microscopy.²⁰ Samples are probed with laser pulses of longer wavelengths but high intensities to stimulate multi photon excitation.²¹ High intensities are required to increase the chance of non-linear multi photon excitations and the laser is generally operated by using long wavelength femto-second pulses of high intensity to decrease phototoxicity and photobleaching.²² Increased *z* penetration and contrast are achieved and only the point of interest is subjected to illumination so photobleaching and phototoxicity are minimised in the surrounding sample.^{20–23}

Recent advances in microscopy to view MTS involve the use of optical coherence tomography (OCT) (Fig. 3b), optical projection tomography (OPT) (Fig. 3c) and light sheet microscopy (LSM) (Fig. 3d) to map MTS. In OCT back scattered or back reflected light is detected to provide cross sectional images through a 3D sample.²⁴ In OPT the sample is rotated and straight line projections are taken through it to generate 3D images.^{25,26} The advantage of OCT and OPT are that much larger sample volumes can be imaged but resolution is much lower than that which can be obtained from sectioned samples viewed through standard high resolution microscopes or by using confocal microscopy.²⁷




Fig. 3 (a) MTS imaged using a light microscope; (b) a cross section through the centre of an MTS using OCT; (c) an OPT image of an MTS derived from a primary cancer specimen where blue core = implanted MTS, green = outgrowth into culture in collagen and red = positive immunoreactivity for Her2; and (d) LSM image of a MTS.⁸

A more recent and very useful microscopy advancement for the analysis of MTS is LSM or single plane illumination microscopy (SPIM). This involves using a light sheet, a plane of light, to illuminate a sample as opposed to a single point. As well as providing an image of a whole specimen slice at once and therefore reducing acquisition time, this technique reduces the light exposure of areas of the sample and therefore reduces photobleaching and phototoxicity.⁸ It is an ideal technique for analysis of MTS as it allows whole sections through MTS to be observed at once and *z* stacks to be built into a 3D image with better *z* resolution than confocal microscopy (Fig. 3d). A disadvantage of this technique is the general need to embed samples in a transparent gel material, usually agarose or low melting point agarose. Embedding in such materials can impact the growth, placing mechanical restraints on specimens and making growth time course experiments inaccurate. Recently, Desmaison, A. *et al.*²⁸ developed a sample holder allowing MTS to be mounted in hydrogel and a time course experiment of MTS growth to be performed.

Further advances have recently been made to LSM including the use of self-reconstructing Bessel beams and two-photon fluorescence excitation which saw an increase of nearly two fold in axial resolution and 5–10 fold increase in contrast in comparison to linear Bessel beam excitation and 3–5 fold increase in *z* penetration depth in comparison to Gaussian beam linear excitation.^{29,30} Very recently LSM has been performed using an Airy beam to provide further advances in particular allowing a larger field of view with high contrast and high resolution.³¹






Fig. 4 comparison of the morphology of cells growing in (a) monolayer culture to (b) cells growing as MTS and (c) a magnified area of cells growing as MTS.

It is worth mentioning some additional microscopy techniques that can reveal morphological characteristics of MTS compared to monolayer culture. Transmission electron microscopy (TEM) has been used to visualise cell-cell³² and cell-ECM³³ interactions in MTS while scanning electron microscopy (SEM) reveals high magnification and high resolution information about the surface characteristics of MTS including visualisation of cell-cell interactions and the morphology of cells.^{34–36} Both techniques require cells to be fixed and processed and SEM only reveals surface topology, with samples often coated in gold removing a lot of surface detail. Helium ion microscopy (HIM) removes the need for coating and provides increased resolution compared to SEM.³⁷ Fig. 4 compares morphology of monolayer cultured cells to MTS using HIM. Table 1 summarises the microscopy techniques used when analysing MTS along with their advantages and limitations.

Measuring oxygen concentration and hypoxia

A significant characteristic of MTS in comparison to monolayer culture is variation in oxygen concentration mimicking *in vivo* tumours. As tumours and MTS grow the central regions become increasingly depleted in oxygen (and hypoxic) and eventually cells may die creating a necrotic core.³⁸ Hypoxia in tumours is incredibly significant as it can induce pro-survival signalling, leading to metabolic changes and resistance to therapy.^{4,5,39,40}

It is desirable to chemically analyse variations in oxygen concentration and hypoxia through MTS. Oxygen concentration and hypoxia are highly interlinked but not identical

characteristics. Oxygen concentration is singularly a measurement of the level of oxygen present while hypoxia is a more complex characteristic which can be defined in several ways including nitroreductase activity,⁴¹ HIF activation⁴² and expression of HIF associated genes⁴³ to name a few. This distinction is important since a hypoxic phenotype (HIF stabilisation, glycolytic metabolism) is a characteristic of many cancers irrespective of oxygen concentration (Warburg Effect).⁴⁴ When considering chemical analysis of MTS some techniques have been developed specifically to measure hypoxia as a function of, for example, nitroreductase activity, while other techniques directly measure oxygen concentration.

One of the first methods developed for measuring hypoxia uses small molecules such as 2-nitroimidazole that are metabolised under hypoxic conditions and subsequently detected.⁴⁵ An example is the commercially available Hypoxyprobe-1TM (PimonidazoleHCl)⁴⁶, where the metabolised product in hypoxic regions is detected by an antibody and subsequently visualized by either a fluorescent tag⁴⁷ or colorimetric detection (Fig. 5). This technique is limited to distinguishing cells below and above a hypoxic limit without giving truly quantitative information. Autoradiography was used in initial detection methods for these probes and extension to magnetic resonance spectroscopy (MRS) and positron emission tomography (PET) allowed non-invasive detection of hypoxia in living systems.^{48–54} Hypoxyprobe-1TM has been used to visualise distributions of hypoxia in MTS, giving good spatial resolution, but its use is limited to fixed sections.

Direct measurement of oxygen concentration can be achieved using oxygen microelectrodes. These have been miniaturised to give increased spatial resolution of oxygen measurements both *in vivo* and *ex vivo*. The main disadvantage is that this is an invasive technique with the risk that the oxygen electrodes perturb their immediate environment and thus distort values obtained.^{41,55}

Recent advances have been made to develop increasingly efficient O₂ sensing probes such as new cell-penetrating phosphorescent probes based on conjugates of Pt(II)-tetrakis(pentafluorophenyl)porphine (PtPFPP) dyes.⁵⁶ The Pt probe was conjugated with glucose which minimised aggregation and self-quenching for measurements in aqueous media and was used to perform high resolution phosphorescence lifetime based O₂ imaging (PLIM) in PC12 MTS. Nanoprobes have also been used *in vivo* to measure reactive oxygen species (ROS) concentrations and hypoxia and these techniques could potentially be applied to MTS models and, with the use of more advanced instrument technologies, allow live 3D imaging through the MTS.⁵⁷


pH and nutrient concentration

Lactate accumulation is common in areas of low oxygen due to increased glycolysis, utilisation of the pentose phosphate pathway and decreased oxidative phosphorylation.⁵⁸ Therefore decreasing oxygen concentration and hypoxia tends to correlate with an increase in lactate accumulation and decreasing pH. Gradients in nutrient concentration including glucose and



Table 1 Summarises microscopy techniques used to visualise MTS along with advantages and limitations of each technique

Microscopy technique	Advantages	Limitations
Standard	Simple	No z depth Primarily fixed and sectioned samples Limited to a maximum of 350 μM z depth z Depth still limited
Confocal	z Depth possible	
Two and multi-photon	Increased z depth and contrast Photobleaching and phototoxicity to surrounding sample minimised	
OCT	Can image whole MTS	Resolution is poorer
OPT	Can image whole MTS	Resolution is poorer
LSM	Can image whole MTS Acquisition time reduced Photobleaching and phototoxicity reduced	Samples typically embedded in a transparent gel which can impact growth
TEM	High resolution to visualise cell-cell and cell-ECM interactions	Limited field of view Involves fixing and processing samples
SEM	High resolution and high magnification of surface characteristics	Involves fixing samples Only reveals surface information Samples often gold coated which removes surface detail
HIM	Increased resolution compared to SEM for revealing surface characteristics No requirement for coating	Involves fixing samples Only reveals surface information

**Fig. 5** Two fluorescent images of MTS stained with Hypoxyprobe-1TM (pink) where cell nuclei are stained blue.

ATP that are intimately linked to changes in metabolic pathways can also correlate with pH and oxygen gradients.

Methods for measuring pH and nutrient concentrations in MTS are limited and primarily based on monolayer techniques. Significantly, studies of pH in tumour cells have revealed that intracellular and extracellular pH differ significantly, with intracellular pH becoming neutral to alkaline and extracellular pH acidic.^{5,59} This intra- and extracellular trend is attributed to ion pumps exporting protons from inside to outside cells which can become activated by certain growth factors which promote tumour angiogenesis, often associated with requirement for increased blood supply in areas of lower oxygen. This gradient of lower extracellular to intracellular pH is the opposite of that observed under normal tissue conditions. Detection of differences between intra- and extracellular environment requires very high resolution techniques which are currently limited.

Most methods to detect pH in culture employ fluorescence and can also be used in MTS, for example the intracellular monitoring dye BCECF.⁶⁰ One of the commonly used tech-

niques to monitor nutrient and pH variations in MTS is bioluminescence imaging. Walenta, S. *et al.*⁶¹ used the technique of bioluminescence of cryosectioned non-proliferating Rat 1 aggregates and MR1 MTS to determine variations in ATP, glucose and lactate. While bioluminescence imaging reveals detailed information about nutrient gradients in MTS with high spatial resolution, the resolution is not sufficient to distinguish intra- and extra-cellular compartments.

The more recent use of nanoprobe for pH imaging *in vivo* also has potential in live MTS. This technique is based on pH sensitive fluorescent probes conjugated to nanoprobe that can also be antibody-targeted to specific cells. Live cell imaging is possible but there is the drawback of limited range of pH detection.⁵⁷ Surface enhanced Raman scattering (SERS) has been used to measure intracellular pH using gold nano-shells functionalised with pH active molecules in monolayer culture.^{62–66} This technique could be extended to MTS and has the potential for multiplexing to allow numerous characteristics, such as pH and redox, to be measured simultaneously.⁶⁷

¹H magnetic resonance chemical shift imaging of MTS incubated with imidazole was used to provide information on pH variations in MTS with $32 \times 32 \mu\text{m}$ resolution. While this resolution is not enough to distinguish intra- and extracellular pH variations it revealed a 0.6 pH unit difference between central and peripheral regions of the MTS.⁶⁸

Spectroscopic imaging techniques have been used to map changes in chemical, elemental and nutrient concentrations in MTS. DLD-1 MTS have been analysed by scanning transmission ion microscopy (STIM), proton-induced X-ray emission (PIXE) mapping, scanning X-ray fluorescence microscopy (SXFM) and Fourier transform infrared (FT-IR). STIM revealed useful information regarding cell density where lower density was observed in central regions relating to the necrotic core. PIXE revealed elemental maps giving information of element density of P, S, Cl, K and Fe. Cu and Zn distribution were



mapped using SXFM while FT-IR revealed detailed information regarding the distribution of different biomolecules such as proteins, lipids and DNA as well as lactate.⁶⁹

Proteins

Primarily as a result of the gradients of, for example, oxygen that develop in MTS, protein expression is often altered. Standard techniques for measuring protein expression such as Western Blotting can be difficult to perform with MTS samples due to the requirement for large numbers of cells, although this problem has been addressed to some extent by techniques such as in-cell westerns.² To overcome this problem multiple MTS for the same conditions can be used. An example study using western blotting shows that the multidrug resistance (MDR1) gene is hypoxia responsive and regulated by Hypoxia Inducible Factor-1 (HIF-1).⁷⁰ Both immunohistochemistry and immunofluorescence can be used to detect and quantify protein expression using specific antibodies. For example, proteins involved in cell–cell and cell–ECM interactions and components of ECM such as cadherins, integrins and collagens respectively can be immunochemically stained. It is also possible to perform quantitative immunofluorescence, for example using Automated Quantitative Analysis (AQUA), which allows quantitation of a target signal *e.g.* Her2 in Fig. 6 in cells stained for cytokeratin (tumour cells).⁷¹ While spatial information can be acquired using these techniques there is the need to fix samples. A similar technique that is also often used and based on fluorescence is flow cytometry of trypsinised samples. While this is simple and can provide quantitative data, it removes the majority of spatial information.^{72,73}

Bioluminescence has also been used to detect protein expression, protein–protein interactions and enzyme activity by employing different versions of the luciferase bioluminescence assay.^{74,75} This is a promising technique as it

has the potential to provide spatial information by live imaging of intact MTS. In comparison to fluorescence, bioluminescence has the advantage of a lower background and therefore better sensitivity, a larger range over which quantitative signal can be obtained and less perturbation by coloured compounds.²

Nanoprobes can be used for the detection of particular enzymes to analyse their expression. For example, a nanoprobe was developed to detect the activity of caspase-3, an enzyme involved in apoptosis, where nanoparticles were conjugated with a caspase-3 substrate and scattering colour varied as individual nanoparticles were released by the enzyme acting to digest the substrate.⁵⁷ This technique was used *in vivo* but has the potential for spatial analysis of differences in enzyme expression in MTS.

A novel demonstration of spatially resolved protein expression information was performed by McMahon,⁷⁶ where MTS layers were progressively trypsinised to isolate the outer proliferating layer, middle peri-necrotic layer and necrotic core. Mass spectrometry using an iTRAQ approach with MALDI-TOF-TOF and ESI-Q-TOF was used to analyse the protein content of each layer and compare and contrast. This new approach was also complemented with traditional techniques including immunohistological staining using GLUT-1 and CAIX antibodies. While this technique does not provide highly resolved spatial information it is the first technique to demonstrate spatial changes in protein expression through MTS.

Another recent and promising technique based on mass spectrometry that provides spatial information on proteins in MTS is mass spectrometry imaging (MSI). Matrix-assisted laser desorption/ionization mass spectrometry (MALDI) has been used to analyse frozen or fixed tissue sections for spatial imaging of protein and peptides as well as other species such as lipids and small molecules.⁷⁷ Typically frozen tissue sections are analysed,⁷⁸ however, this technique has also been performed on formalin-fixed, paraffin-embedded tissue sections.⁷⁹ To limit analyte spreading during preparation, matrix-free MSI has also been developed.⁸⁰ In addition to tissue sections MALDI imaging has been performed on sectioned MTS embedded in collagen to give information on protein variations through the structure. Proteins were identified using MALDI-TOF-TOF and nanoflow-LC-MS/MS of lysates from MTS and cytochrome C and histone H were both detected as two of the species mapped. This technique is useful as it provides spatially resolved information without the need for specific stains such as those used in immunohistochemistry and immunofluorescence. However it still requires samples to be fixed or frozen and sectioned and therefore live samples cannot be analysed.

Another emerging and promising technique for chemical analysis of MTS is Raman imaging. This technique is a label free and non-invasive technique for probing differences in chemical composition. Raman imaging probes the vibrational modes of molecules giving information on the chemical composition of the area being probed in a spatially resolved




Fig. 6 Quantitative immunofluorescence using AQUA to quantify target signal (Her2, red, top right) in cells marked for cytokeratin (*i.e.* tumour cells, green, top left) in MTS. Nuclei are stained with DAPI (blue, bottom right). All fluorescent signals are combined in the bottom left image.



manner. This technique has been predominantly investigated in monolayer culture but recently it has been shown to be useful for the analysis of 3D MTS culture also.⁸¹ While still in its initial stages of research, this technique is very promising for live and label free chemical imaging of MTS.

The techniques of MSI and confocal Raman imaging (CRI) have been combined to provide enhanced chemical information, combining information on integrity of cells and protein levels using CRI and small molecule location using MSI.⁸² In this example, MTS were fixed, processed and sectioned for analysis. While CRI has potential for live cell imaging of whole MTS, MSI is only possible on sectioned samples.

Localisation of and cellular response to drugs

The development of the MTS model and techniques to chemically analyse and characterise MTS has provided a more realistic *ex vivo* model of cancer. In addition to increasing insight into physiological characteristics of MTS, this provides a platform for more effective testing of drug candidates and therapies.⁸³ Screening of drug candidates on MTS gives more reliable results saving time and money in later stages of drug trials. Recent developments in high throughput screening have allowed MTS to be used in place of monolayer culture, allowing drug candidates to be better selected for efficacy.^{13,34,84}

The interesting technique of biodynamic imaging has been used to analyse cellular response to drugs toxic to mitochondria and B-Raf inhibitors.⁸⁵ This is an optical technique which monitors dynamic changes in cells over time and how these changes vary when treated with a particular drug. Biodynamic imaging detects dynamic light scattering using low-coherence digital holography to elucidate information on intracellular motions. Such motions include dynamic processes in cells including organelle movement and cytoskeletal changes that are often affected by drug treatment. The effect of drugs affecting the mitochondria and Raf kinase inhibitors on two colon cancer cell lines was investigated using this biodynamic imaging technique.

Nanomedicine is a rapidly advancing area of cancer research. It is apparent that when developing promising nanoparticle based techniques for cancer therapy, imaging technologies capable of successful visualising the 3D MTS structure are essential. As already discussed the advances in instrument technology, primarily with OCT, OPT and LSM, allows successful 3D images of MTS to be formed. Fluorescent LSM would be particularly useful for monitoring nanoparticle uptake if nanoparticles could be fluorescently labelled. Studies have investigated the use of techniques such as fluorescence lifetime imaging microscopy (FLIM) to examine the distribution of doxorubicin (DOX) functionalised iron oxide nanoparticles where native DOX released from the nanoparticles had a different fluorescence lifetime to DOX conjugated to the nanoparticles allowing distinction between released and conjugated DOX to be investigated.⁸⁶ In another study 3D multiphoton fluorescence microscopy was successfully employed to investigate the uptake of quantum dots and DOX encapsulated in micelles.³⁶

MALDI imaging has also been used to monitor drug uptake in MTS. Both the drug irinotecan and its metabolites were imaged by MALDI in HCT 116 colon cancer MTS at various time points to investigate uptake and metabolism of the drug.⁸⁷ Raman imaging also has potential for use in drug uptake studies in MTS.⁸¹

Conclusions

MTS are now established as a valuable *in vitro* tool for investigation of tumour physiology and response to drugs and therapy. There is a need for these models due to the limitations of monolayer culture in displaying the complex characteristics found *in vivo* as a result of their 2D rather than 3D nature. This includes characteristics such as lack of cell-cell and cell-ECM interactions and failure to develop the gradients found in tumours where central regions become deprived of oxygen and nutrients – a very important characteristic as limited penetration to these areas by drugs and oxygen leads to resistance to many therapies. However, the increasing use of the more physiologically relevant MTS model has led to the requirement of more sophisticated functional imaging, in real time and in three dimensions, and chemical analysis techniques to characterise the physiological environment of these MTS and monitor responses to drugs and therapy, particularly for use in high throughput screening methods.

The fundamental consideration when chemically analysing MTS is choice of a suitable technique and instrumentation to obtain the desired spatial, chemical and 3D resolution. Conventional light and confocal fluorescence microscopy techniques can be used to successfully image whole MTS with limited *z* depth, whilst immunohistochemistry and immunofluorescence can be used to image processed and sectioned samples. Improvements to confocal microscopy along with the use of two- and multiphoton techniques allows increasing *z* penetration depth. The techniques of OCT, OPT and particularly LSM have allowed whole MTS samples to be viewed and advanced our understanding of MTS.

There is still huge potential for development in analysis of MTS as many of the techniques currently used are based on analysing lysed MTS which removes spatial information or fixing and processing MTS which can introduce artefacts and does not allow for real time imaging. Variants of traditional techniques including flow cytometry, immunohistochemistry, immunofluorescence, bioluminescence imaging and western blotting are currently the main techniques employed for monitoring various chemical characteristics of MTS. There is constant development of new techniques to allow real time analysis of live MTS and perhaps the most promising areas for development is in the use of nanoprobe and Raman imaging. The combination of new probes, new imaging techniques and improved culture techniques will help drive MTS use into the mainstream of drug discovery. This review has highlighted these latest areas pushing the limits of chemical analysis of MTS and enabling technologies for imaging results. Table 2





Table 2 Summarises the enabling technologies discussed for chemical analysis of MTS along with their uses and limitations

Enabling technology	Use	Limitations
Hypoxia probes <i>e.g.</i> Hypoxyprobe™	Hypoxia detection	Sample has to be fixed and sectioned Only detects above/below a certain hypoxic threshold
Oxygen microelectrodes	Measure oxygen concentration	Invasive so can perturb environment
Cell penetrating phosphorescent probes	O ₂ sensing	Delivery of probes to cells
Nanoprobes	ROS detection pH detection Enzyme activity	Delivery of nanoprobes to cells
Fluorescent dyes	pH detection	Limited pH detection range
Bioluminescence imaging	pH and nutrient detection	Intra- and extra-cellular compartments cannot be distinguished
	Protein expression protein–protein interactions	
	Enzyme activity	
¹ H magnetic resonance chemical shift imaging	pH detection	Intra- and extra-cellular compartments cannot be distinguished
Spectroscopic imaging	Cell density (STIM)	Samples have to be frozen and sectioned
	Element density (PIXE and SXFM)	
	Protein, lipid, DNA and lactate distribution (FT-IR)	
Western blotting	Protein expression	Spatial information lost
Immunohistochemistry and immunofluorescence	Protein expression	Samples have to be fixed and processed
Flow cytometry	Protein expression	Spatial information limited
Mass spectrometry	Protein expression	Spatial resolution possible but limited
Mass spectrometry imaging	Protein expression	Samples have to be frozen and sectioned
	Lipid and small molecule expression	
	Drug uptake and metabolism	
Raman imaging	Chemical composition Molecule distribution	Promising but limited research so far
SERS	pH and redox potential measurement	Delivery of nanoprobes to cells
Biodynamic imaging	Monitoring dynamic changes in response to drug	Monitors motions only
FLIM	Drug release	Promising but limited use so far

summarises the techniques discussed for chemical analysis of MTS.

Acknowledgements

The authors gratefully acknowledge Peter Mullen for providing the image in Fig. 2b and Fig. 5; Dr A Leeper for use of the image in Fig. 3c; Dr Pierre Bagnaninchi for acquisition of the OCT image in Fig. 3b; Dr S Langdon for use of the image in Fig. 2d; and Prof. Ernst Stelzer for permission to use the image I Fig. 3d. This research received support from the QNano Project <http://www.qnano-ri.eu> which is financed by the European Community Research Infrastructures under the FP7 Capacities Programme (grant no. INFRA-2010-262163), and its partner Trinity College Dublin.

Notes and references

- H. Page, P. Flood and E. G. Reynaud, *Cell Tissue Res.*, 2013, **352**, 123–131.
- G. Mehta, A. Y. Hsiao, M. Ingram, G. D. Luker and S. Takayama, *J. Controlled Release*, 2012, **164**, 192–204.
- L. A. Kunz-Schughart, P. Heyder, J. Schroeder and R. Knuechel, *Exp. Cell Res.*, 2001, **266**, 74–86.
- D. Hanahan and R. A. Weinberg, *Cell*, 2011, **144**, 646–674.
- P. Vaupel, *Semin. Radiat. Oncol.*, 2004, **14**, 198–206.
- A. S. Mikhail, S. Eetezadi, S. N. Ekdawi, J. Stewart and C. Allen, *Int. J. Pharm.*, 2014, **464**, 168–177.
- R.-Z. Lin and H.-Y. Chang, *Biotechnol. J.*, 2008, **3**, 1172–1184.
- F. Pampaloni, N. Ansari and E. H. K. Stelzer, *Cell Tissue Res.*, 2013, **352**, 161–177.
- H.-G. Kang, J. M. Jenabi, J. Zhang, N. Keshelava, H. Shimada, W. A. May, T. Ng, C. P. Reynolds, T. J. Triche and P. H. B. Sorensen, *Cancer Res.*, 2007, **67**, 3094–3105.
- J. Holtfreter, *J. Exp. Zool.*, 1944, **95**, 171–212.
- A. Moscona and H. Moscona, *J. Anat.*, 1952, **86**, 287–301.
- Using Perfecta3D™ *Hanging Drop Plates to Assess Chemosensitivity (White Paper)*, 3D Biomatrix™, <https://3dbiomatrix.com/wp-content/uploads/downloads/2011/11/3D-Biomatrix-White-Paper-Hanging-Drop-Plate.pdf> (accessed March 2015).
- Y.-C. Tung, A. Y. Hsiao, S. G. Allen, Y. Torisawa, M. Ho and S. Takayama, *Analyst*, 2011, **136**, 473–478.
- G. Hamilton, *Cancer Lett.*, 1998, **131**, 29–34.
- F. Hirschhaeuser, H. Menne, C. Dittfeld, J. West, W. Mueller-Klieser and L. A. Kunz-Schughart, *J. Biotechnol.*, 2010, **148**, 3–15.
- A. L. van Wezel, *Nature*, 1967, **216**, 64–65.
- J. Comley, *Drug Discovery World*, 2010 (summer), 25–41.
- H. Hardelauf, J.-P. Frimat, J. D. Stewart, W. Schormann, Y.-Y. Chiang, P. Lampen, J. Franzke, J. G. Hengstler, C. Cadenas, L. A. Kunz-Schughart and J. West, *Lab Chip*, 2011, **11**, 419–428.

- 19 L. le Roux, D. Schellingerhout, A. Volgin, D. Maxwell, K. Ishihara and J. Gelovani, *Microsc. Microanal.*, 2008, **14**, 734–735.
- 20 R. M. Williams, W. R. Zipfel and W. W. Webb, *Curr. Opin. Chem. Biol.*, 2001, **5**, 603–608.
- 21 W. R. Zipfel, R. M. Williams and W. W. Webb, *Nat. Biotechnol.*, 2003, **21**, 1369–1377.
- 22 V. E. Centonze and J. G. White, *Biophys. J.*, 1998, **75**, 2015–2024.
- 23 K. König, A. Uchugonova and E. Gorjup, *Microsc. Res. Tech.*, 2011, **74**, 9–17.
- 24 J. G. Fujimoto, C. Pitris, S. A. Boppart and M. E. Brezinski, *Neoplasia*, 2000, **2**, 9–25.
- 25 J. Sharpe, *Annu. Rev. Biomed. Eng.*, 2004, **6**, 209–228.
- 26 J. Sharpe, U. Ahlgren, P. Perry, B. Hill, A. Ross, J. Hecksher-Sørensen, R. Baldock and D. Davidson, *Science*, 2002, **296**, 541–545.
- 27 M. Sharma, Y. Verma, K. D. Rao, R. Nair and P. K. Gupta, *Biotechnol. Lett.*, 2007, **29**, 273–278.
- 28 A. Desmaison, C. Lorenzo, J. Rouquette, B. Ducommun and V. Lobjois, *J. Microsc.*, 2013, **251**, 128–132.
- 29 F. O. Fahrback, V. Gurchenkov, K. Alessandri, P. Nassoy and A. Rohrbach, *Opt. Express*, 2013, **21**, 13824–13839.
- 30 O. E. Olarte, J. Andilla, R. Jorand, B. Ducommun, C. Lorenzo and P. Loza-Alvarez, http://www.focusonmicroscopy.org/2013/PDF/392_Olarte.pdf (accessed March 2015).
- 31 T. Vettenburg, H. I. C. Dalgarno, J. Nylk, C. Coll-Lladó, D. E. K. Ferrier, T. Čížmár, F. J. Gunn-Moore and K. Dholakia, *Nat. Methods*, 2014, **11**, 541–544.
- 32 R. M. Sutherland, J. A. McCredie and W. R. Inch, *J. Natl. Cancer Inst.*, 1971, **46**, 113–120.
- 33 T. Nederman, B. Norling, B. Glimelius, J. Carlsson and U. Brunk, *Cancer Res.*, 1984, **44**, 3090–3097.
- 34 W. Y. Ho, S. K. Yeap, C. L. Ho, R. A. Rahim and N. B. Alitheen, *PLoS One*, 2012, **7**, e44640.
- 35 M. T. Santini, G. Rainaldi and P. L. Indovina, *Crit. Rev. Oncol. Hematol.*, 2000, **36**, 75–87.
- 36 H. Ma, Q. Jiang, S. Han, Y. Wu, J. C. Tomshine, D. Wang, Y. Gan, G. Zou and X.-J. Liang, *Mol. Imaging*, 2012, **11**, 487–498.
- 37 G. Hlawacek, V. Veligura, R. van Gastel and B. Poelsema, *J. Vac. Sci. Technol., B*, 2014, **32**, 020801.
- 38 T. Anada, J. Fukuda, Y. Sai and O. Suzuki, *Biomaterials*, 2012, **33**, 8430–8441.
- 39 A. Hunter, A. Hendrikse, M. Renan and R. Abratt, *Apoptosis*, 2006, **11**, 1727–1735.
- 40 H. Harada, *J. Radiat. Res.*, 2011, **52**, 545–556.
- 41 K. A. Krohn, J. M. Link and R. P. Mason, *J. Nucl. Med.*, 2008, **49**, 129S–148S.
- 42 M. W. Dewhirst, Y. Cao and B. Moeller, *Nat. Rev. Cancer*, 2008, **8**, 425–437.
- 43 G. L. Semenza, *Nat. Rev. Cancer*, 2003, **3**, 721–732.
- 44 W. H. Koppenol, P. L. Bounds and C. V. Dang, *Nat. Rev. Cancer*, 2011, **11**, 325–337.
- 45 A. J. Varghese, S. Gulyas and J. K. Mohindra, *Cancer Res.*, 1976, **36**, 3761–3765.
- 46 *HypoxyprobeTM-1 Plus Kit for the Detection of Tissue Hypoxia*, Chemicon International, http://webcache.googleusercontent.com/search?q=cache:8bxU7yy_OUoJ:www.ibrarian.net/navon/paper/HypoxyprobeTM_1_Plus_Kit_for_the_Detection_of_Tis.pdf%3Fpaperid%3D4633961+&cd=5&hl=en&ct=clnk&gl=uk (accessed March 2015).
- 47 J. A. Raleigh, G. G. Miller, A. J. Franko, C. J. Koch, A. F. Fuciarelli and D. A. Kelly, *Br. J. Cancer*, 1987, **56**, 395–400.
- 48 J. D. Chapman, A. J. Franko and J. Sharplin, *Br. J. Cancer*, 1981, **43**, 546–550.
- 49 J. D. Chapman, K. Baer and J. Lee, *Cancer Res.*, 1983, **43**, 1523–1528.
- 50 A. J. Franko and C. J. Koch, *Int. J. Radiat. Oncol. Biol. Phys.*, 1984, **10**, 1333–1336.
- 51 A. J. Varghese and G. F. Whitmore, *Int. J. Radiat. Oncol. Biol. Phys.*, 1984, **10**, 1341–1345.
- 52 J. A. Raleigh, A. J. Franko, C. J. Koch and J. L. Born, *Br. J. Cancer*, 1985, **51**, 229–235.
- 53 R. C. Urtasun, C. J. Koch, A. J. Franko, J. A. Raleigh and J. D. Chapman, *Br. J. Cancer*, 1986, **54**, 453–457.
- 54 J. A. Raleigh, D. P. Calkins-Adams, L. H. Rinker, C. A. Ballenger, M. C. Weissler, W. C. Fowler, D. B. Novotny and M. A. Varia, *Cancer Res.*, 1998, **58**, 3765–3768.
- 55 B. Bourrat-Floek, K. Groebe and W. Mueller-Klieser, *Int. J. Cancer*, 1991, **47**, 792–799.
- 56 R. I. Dmitriev, A. V. Kondrashina, K. Koren, I. Klimant, A. V. Zhdanov, J. M. P. Pakan, K. W. McDermott and D. B. Papkovsky, *Biomater. Sci.*, 2014, **2**, 853–866.
- 57 H. Koo, M. S. Huh, J. H. Ryu, D.-E. Lee, I.-C. Sun, K. Choi, K. Kim and I. C. Kwon, *Nano Today*, 2011, **6**, 204–220.
- 58 C. Riganti, E. Gazzano, M. Polimeni, E. Aldieri and D. Ghigo, *Free Radicals Biol. Med.*, 2012, **53**, 421–436.
- 59 M. K. Danquah, X. A. Zhang and R. I. Mahato, *Adv. Drug Delivery Rev.*, 2011, **63**, 623–639.
- 60 D. Rotin, D. Steele-Norwood, S. Grinstein and I. Tannock, *Cancer Res.*, 1989, **49**, 205–211.
- 61 S. Walenta, J. Doetsch, W. Mueller-Klieser and L. A. Kunz-Schughart, *J. Histochem. Cytochem.*, 2000, **48**, 509–522.
- 62 A. Jaworska, L. E. Jamieson, K. Malek, C. J. Campbell, J. Choo, S. Chlopicki and M. Baranska, *Analyst*, 2015, **140**, 2321.
- 63 S. W. Bishnoi, C. J. Rozell, C. S. Levin, M. K. Gheith, B. R. Johnson, D. H. Johnson and N. J. Halas, *Nano Lett.*, 2006, **6**, 1687–1692.
- 64 J. Kneipp, H. Kneipp, B. Wittig and K. Kneipp, *Nano Lett.*, 2007, **7**, 2819–2823.
- 65 J. Kneipp, H. Kneipp, B. Wittig and K. Kneipp, *J. Phys. Chem. C*, 2010, **114**, 7421–7426.
- 66 M. A. Ochsenkuehn, P. R. T. Jess, H. Stoquert, K. Dholakia and C. J. Campbell, *ACS Nano*, 2009, **3**, 3613–3621.
- 67 L. E. Jamieson, A. Jaworska, J. Jiang, M. Baranska, D. J. Harrison and C. J. Campbell, *Analyst*, 2015, **140**, 2330.
- 68 J. Alvarez-Pérez, P. Ballesteros and S. Cerdán, *MAGMA*, 2005, **18**, 293–301.



- 69 J. Z. Zhang, N. S. Bryce, R. Siegele, E. A. Carter, D. Paterson, M. D. de Jonge, D. L. Howard, C. G. Ryan and T. W. Hambley, *Integr. Biol.*, 2012, **4**, 1072–1080.
- 70 K. M. Comerford, T. J. Wallace, J. Karhausen, N. A. Louis, M. C. Montalto and S. P. Colgan, *Cancer Res.*, 2002, **62**, 3387–3394.
- 71 R. L. Camp, G. G. Chung and D. L. Rimm, *Nat. Med.*, 2002, **8**, 1323–1328.
- 72 N.-C. Cheng, S. Wang and T.-H. Young, *Biomaterials*, 2012, **33**, 1748–1758.
- 73 J. M. Lee, P. Mhawech-Fauceglia, N. Lee, L. C. Parsanian, Y. G. Lin, S. A. Gayther and K. Lawrenson, *Lab. Invest.*, 2013, **93**, 528–542.
- 74 P. M. Tiwari, K. Vig, V. A. Dennis and S. R. Singh, *Nanomaterials*, 2011, **1**, 31–63.
- 75 E. Salomonsson, A. C. Stacer, A. Ehrlich, K. E. Luker and G. D. Luker, *PLoS One*, 2013, **8**, e51500.
- 76 K. McMahon, *PhD Thesis*, University of Bradford, 2011.
- 77 R. J. A. Goodwin, S. R. Pennington and A. R. Pitt, *Proteomics*, 2008, **8**, 3785–3800.
- 78 M. Stoeckli, P. Chaurand, D. E. Hallahan and R. M. Caprioli, *Nat. Med.*, 2001, **7**, 493–496.
- 79 M. C. Djidja, E. Claude, M. F. Snel, P. Scriven, S. Francese, V. Carolan and M. R. Clench, *J. Proteome Res.*, 2009, **8**, 4876–4884.
- 80 R. J. A. Goodwin, A. R. Pitt, D. Harrison, S. K. Weidt, P. R. R. Langridge-Smith, M. P. Barrett and C. L. MacKay, *Rapid Commun. Mass Spectrom.*, 2011, **25**, 969–972.
- 81 E. Zuser, *PhD Thesis*, Northeastern University, 2013.
- 82 D. R. Ahlf, R. N. Masyuko, A. B. Hummon and P. W. Bohn, *Analyst*, 2014, **139**, 4578–4585.
- 83 W. Fayad, L. Rickardson, C. Haglund, M. H. Olofsson, P. D'Arcy, R. Larsson, S. Linder and M. Fryknäs, *Chem. Biol. Drug Des.*, 2011, **78**, 547–557.
- 84 B. G. Reid, T. Jerjian, P. Patel, Q. Zhou, B. H. Yoo, P. Kabos, C. A. Sartorius and D. V. LaBarbera, *Curr. Chem. Genomics Transl. Med.*, 2014, **8**, 27–35.
- 85 R. An, D. Merrill, L. Avramova, J. Sturgis, M. Tsiper, J. P. Robinson, J. Turek and D. D. Nolte, *J. Biomol. Screening*, 2014, **19**, 526–537.
- 86 J. S. Basuki, H. T. T. Duong, A. Macmillan, R. B. Erlich, L. Esser, M. C. Akerfeldt, R. M. Whan, M. Kavallaris, C. Boyer and T. P. Davis, *ACS Nano*, 2013, **7**, 10175–10189.
- 87 X. Liu, E. M. Weaver and A. B. Hummon, *Anal. Chem.*, 2013, **85**, 6295–6302.

